Nanogen, Epoch Biosciences, IntegraGen, La Ligue Nationale Contre le Cancer, PerkinElmer, Procognia, Accelr8, Ciphergen | GenomeWeb

Nanogen Closes Acquisition of Epoch Biosciences

Nanogen last week closed its acquisition of Epoch Biosciences for $97 million. The deal was originally announced in September, and was approved by shareholders on Dec. 15.

Epoch ceased trading on the Nasdaq exchange at market close last Thursday.

Nanogen shareholders approved the issuance of shares of common stock for the deal, and also approved an amendment to the company’s certificate of incorporation increasing the number of authorized shares of Nanogen common stock to 135 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.